Integra lifesciences (NASDAQ: IART) and HTG Molecular Diagnostics (NASDAQ:HTGM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Earnings & Valuation
This table compares Integra lifesciences and HTG Molecular Diagnostics’ gross revenue, earnings per share and valuation.
||Earnings Per Share
|HTG Molecular Diagnostics
Integra lifesciences has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Integra lifesciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
89.7% of Integra lifesciences shares are held by institutional investors. Comparatively, 8.4% of HTG Molecular Diagnostics shares are held by institutional investors. 5.1% of Integra lifesciences shares are held by insiders. Comparatively, 7.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Integra lifesciences and HTG Molecular Diagnostics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
|HTG Molecular Diagnostics
This is a summary of recent recommendations for Integra lifesciences and HTG Molecular Diagnostics, as provided by MarketBeat.
||Strong Buy Ratings
|HTG Molecular Diagnostics
Integra lifesciences presently has a consensus price target of $58.42, indicating a potential downside of 9.56%. HTG Molecular Diagnostics has a consensus price target of $7.00, indicating a potential upside of 89.70%. Given HTG Molecular Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe HTG Molecular Diagnostics is more favorable than Integra lifesciences.
Volatility and Risk
Integra lifesciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Integra lifesciences beats HTG Molecular Diagnostics on 9 of the 14 factors compared between the two stocks.
About Integra lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.